Genscript Biotech (HKG:1548) plans to spin off and separately list its indirect non-wholly owned subsidiary Probio Technology on the Hong Kong Stock Exchange's main board, according to a Friday bourse filing.
The company said it will retain a controlling interest in ProBio after the spin-off, and ProBio will remain a subsidiary with its financial results consolidated into the group's accounts.
Details of the proposed listing have yet to be finalized and remain subject to final regulatory approval, market conditions, and other considerations.
ProBio operates the group's biologics and advanced therapy contract research, development, and manufacturing services, according to the filing.